Published on Spencer Knight via LinkedIn Spencer Knight shares a compelling visual breakdown of 187 gene editing companies across four...

Published on Spencer Knight via LinkedIn 21-year-old Sebastien Beauzile spent his life in constant pain from sickle cell disease, unable...

Published on Spencer Knight via LinkedIn CAR-T once promised a revolution, then came the cost, complexity, and clinical setbacks. Spencer...

Published on Spencer Knight via LinkedIn Sana Biotechnology has announced successful first-in-human results using HIP-engineered islet...

Published on Repligen Poster, Bioprocessing Summit (July 2023) With biologics becoming more complex and global manufacturing capacity...

Published on Repligen White Paper (July 2022) Facing growing demand for veterinary vaccines, MSD Animal Health partnered with Repligen to...

Published on Repligen Application Note (Sept 2024) Lentiviral vector production is a major bottleneck in CAR-T manufacturing, but...

Published on Repligen Scientific Poster (Sept 2022) To meet growing demand in gene therapy, Repligen scientists applied tangential flow...

Published on Repligen Brochure (Nov 2024) Repligen’s XCell ATF System brings upstream process intensification to life by enabling...

Published on The Borneo Post (June 14, 2025) Sarawak has officially launched the Sarawak Society for Cell and Gene Therapy...

Published on Temple University News (August 28, 2024) In a major preclinical breakthrough, researchers at Temple University and Excision...

Published on Lonza White Paper (CD-DS008) Choosing the right transfection method is key in gene therapy and biomedical research. This...

Published on Lonza White Paper (CT-SP008) Cell therapy manufacturing is often held back by viral vector limitations and labor-intensive...

Published on Lonza Overview (CT-SP019) Scaling cell therapy from benchtop to bedside requires technologies that are efficient, compliant,...

Published on Lonza Poster Presentation (CT-SP020) Gamma delta (γδ) T cells are gaining momentum as a promising cell therapy platform due...

Published on Lonza Poster Presentation (CT-PO024) Non-viral electroporation continues to gain ground as a safer, scalable alternative to...

Published on Cell & Gene The U.S. FDA has approved the first product under its new Advanced Manufacturing Technology (AMT) designation, a...

Published on Cell & Gene As gene therapy evolves, so must the validation strategies behind its assays. This article outlines...

Published on Cell & Gene Global regulatory requirements are evolving fast, especially in cell and gene therapy. This article outlines...

Published on Cell & Gene Speed and transparency in clinical data review are vital for regulatory approval. This article looks at how...